Another compounding group shuts amid outbreak

As the meningitis outbreak spreads, so does the fallout from it. A second company in Massachusetts is suspending operations, The Boston Globe reports, while officials investigate. Meanwhile, calls for tougher oversight of pharmaceutical compounding are, predictably, intensifying.

Ameridose--a compounding group that shares ownership with the outbreak's apparent epicenter, New England Compounding--"proactively and voluntarily" agreed to stop manufacturing and compounding, said Dr. Madeleine Biondolillo, director of Massachusetts' Bureau of Healthcare Safety. At the same time, its distribution partner, Alanaus Pharmaceuticals, will stop shipping all of Ameridose's products.

Though New England Compounding has now recalled all its products, none of Ameridose's products are affected, and state officials haven't asked the company to conduct a recall.

News of the outbreak has taken center stage, highlighting the patchwork of state regulations that govern the compounding pharmacy business. Lawmakers are calling for federal oversight. But as Massachusetts Gov. Deval Patrick pointed out yesterday, a lack of rules may not be the problem: New England Compounding is suspected of violating its state license by selling drugs in bulk, rather than prescription by prescription.

The state has now asked all its compounding pharmacies to sign affidavits promising that they're operating within the bounds of their licenses. "There is a gray area where some organizations may have operated contra to the licensing regulations," said Biondolillo, who emphasized that the investigation is ongoing.

- read the Boston Globe story
- get more from The Wall Street Journal

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.